US Serial No. 10/522276 Page 8 of 13

Remarks:

Regarding the amendments to the claims:

Kindly enter the foregoing indicated amendments to the claims without prejudice or traverse. The applicant expressly reserves their right to reinstate subject matter canceled by the present amendments at a later time, such as in the present application or in one or more further applications to be filed at a later date.

Regarding the rejection of claims 1-3, 7 and 12 under 35 USC 102(b) in view of WO99/28428 to Cheung et al.:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Cheung reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1-4, 7, 8, and 12 under 35 USC 102(b) in view of EP 651048 to Gardella:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Gardella reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1-5, 7-9 and 12 under 35 USC 102(b) in view of EP 691397 to Zhou:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Zhou reference.

US Serial No. 10/522276 Page 9 of 13

Parfomak

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1-5, 7-9 under 35 USC 102(b) in view of US 6339057 to Knox:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Knox reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1-5, 7-9 and 12 under 35 USC 102(e) in view of US 6667287 to Aszman:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Aszman reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1-5, 7-9 and 12 under 35 USC 102(e) in view of US 6821943 to Avery:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Avery reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

US Serial No. 10/522276 Page 10 of 13

Parfomak

Regarding the rejection of claims 1-5, 7-9 and 12 under 35 USC 102(e) in view of US 5985813 to Arvanitidou:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Arvanitidou reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1-4, 7, 8 and 12 under 35 USC 102(b) in view of US 4464293 to Dobrin:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Dobrin reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1-5, 7-9 and 12 under 35 USC 102(b) in view of US 5925681 to Crisanti:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Crisanti reference.

The applicants' amendment to independent claims 1 and 7, respectively incorporating in the limitations of prior claim 6 and 10 which now require that a propellant be present in the compositions is believed to address and overcome the rejection.

Regarding the rejection of claims 1, 4, 6 and 12 under 35 USC 102(b) in view of US 5948741 to Ochomogo:

US Serial No. 10/522276 Page 11 of 13

Parfomak

The applicant respectfully traverses the rejection of the foregoing claims in view of the Ochomogo reference.

The applicants amendments to the claims presented in this paper are believed to exclude Ochomogo's "(c) a chelating agent selected from the group consisting of tetrapotassium ethylenediamine-tetraacetate, tetraammonium ethylenediamine-tetraaacetate and mixtures thereof, .." and thus are believed to address and overcome the Examiner's rejection under 35 USC 102(b).

Regarding the rejection of claims 7, 8 and 10 under 35 USC 102(b) and/or 103(a) in view of US 5948741 to Ochomogo:

The applicant respectfully traverses the rejection of the foregoing claims in view of the Ochomogo reference.

The applicants amendments to the claims presented in this paper are believed to exclude Ochomogo's "(c) a chelating agent selected from the group consisting of tetrapotassium ethylenediamine-tetraacetate, tetraammonium ethylenediamine-tetraaacetate and mixtures thereof, .." and thus are believed to address and overcome the Examiner's rejection under 35 USC 102(b).

With respect to the Examiner's rejection of claims 7, 8 and 10, the applicant believes that the presently amended claims should be considered an non-obvious over the Ochomogo reference as well. As is evident from a review of Ochomogo, that patentee specifically teaches that his chelating agents are limited to chelating agents which are selected from tetrapotassium ethylenediamine-tetraacetate, tetraammonium ethylenediaminetetraaacetate and mixtures thereof, as Ochomogo states that:

"The chelating agent is a critical part of the invention. Its use, in place of the standard chelating agent, tetrasodium EDTA, results in not only a surprisingly complete removal of various soils, including bathroom soap scum soils, but an unexpectedly rapid removal as well." (Ochomogo, col. 6, lines 5 - 10).

US Serial No. 10/522276 Page 12 of 13

Parfomak

Thus, the presence of tetrapotassium ethylenediamine-tetraacetate, tetraammonium ethylenediamine-tetraaacetate and mixtures thereof is a critical teaching and critical requirement of Ochomogo's compositions. Applicant's presently claimed compositions require neither tetrapotassium ethylenediamine-tetraacetate, tetraammonium ethylenediamine-tetraaacetate and/or mixtures thereof and yet provide excellent technical performance. Furthermore, the present applicant notes that while Ochomogo discusses at col. 6, line 33 et seq. a number of further optional constituents which might be included in his compositions, further chelating agents are conspicuously absent from the recitation at that part of his specification. This absence conforms to Ochomogo's prior teaching that his chelating constituent "... selected from the group consisting of ..." would confirm that any other chelating agents are to be excluded from Ochomogo's compositions. Thus, Ochomogo provides no teaching or suggestion as to the utility of any other chelating constituents other than his tetrapotassium ethylenediaminetetraacetate, tetraammonium ethylenediamine-tetraaacetate and mixtures thereof, and fairly stated, teaches away from the use of chelating agents other than tetrapotassium ethylenediamine-tetraacetate, tetraammonium ethylenediamine-tetraacetate and mixtures thereof which are essential to his compositions.

In view of the applicant's amendments to the claims, and in view of the foregoing remarks concerning Ochomogo, reconsideration of the propriety of the Ochomogo reference and withdrawal from further consideration is solicited.

Should the Examiner in charge of this application believe that telephonic communication with the undersigned would meaningfully advance the prosecution of this application, they are invited to call the undersigned at their earliest convenience.

CONDITIONAL AUTHORIZATION FOR FEES

Should any further fee be required by the Commissioner in order to permit the timely entry of this paper, the Commissioner is authorized to charge any such fee to Deposit Account No. 14-1263.

US Serial No. 10/522276 Page 13 of 13

Parfomak

Respectfully Submitted;

Reg.No. 32,431

Norris, McLaughlin & Marcus, PC 110 East 42nd St., 30th Floor

New York, NY 10017

Tel: 212 808-0700

Certification of Telefax Transmission:

I hereby certify that this paper is being telefax transmitted to the US Patent and Trademark Office to telefax number: 571 273-8300 on the date shown below:

D:\ANPCMB\102792\411\Amendment01.doc